Stem Cell Kidney Organoids Advance AKI Research and Regenerative Medicine

Researchers have made significant strides in kidney organoid research, with new platforms offering human-derived systems for studying acute kidney injury (AKI) and advancing regenerative medicine. A study published in Genome Medicine describes a living kidney organoid model developed at Monash University that reproduces key features of human kidney injury, providing a platform to investigate why some kidney cells recover while others progress towards chronic disease. Separately, scientists at the University of Southern California have successfully created artificial "progenitor" nephron cells to form "renal organoids," miniature kidneys that mimic key parts of the real organ.

The Monash University organoid platform, grown from stem cells, could give early drug discovery researchers a more human-relevant system to investigate potential treatments before they progress towards clinical testing. AKI is a sudden decline in kidney function that can occur following major surgery, transplantation or exposure to certain medicines including chemotherapy, and affects up to 20 percent of hospital admissions, according to Professor John Kanellis, Director of Nephrology at Monash Health. Despite its clinical impact, there are limited treatments that directly promote kidney recovery after AKI. The new platform allows researchers to recreate aspects of kidney injury in human-derived tissue and examine how different cell populations respond, with the goal of identifying treatments that could protect the kidney or improve recovery after injury. Dr Alexander Combes, Head of the Development and Disease Laboratory and Director of the Monash Genome Modification Platform, stated that the team is now using the organoid platform to screen potential therapies, including existing medicines that could potentially be repurposed for kidney injury.

At the University of Southern California, researchers generated artificial "progenitor" nephron cells — the cells that eventually form mature nephrons — and used them to build 3D renal organoids. By adjusting the activity of two proteins, p38 and YAP, the scientists were able to make these cells, both mouse and human, multiply for long periods in the lab as stable cell lines. The lab-grown nephron progenitor cells (NPCs) supported sustained growth of both mouse and human stem cells, and when researchers examined the nephrons produced by these NPCs, they found they were strikingly similar to real human kidney progenitor cells. The team also discovered that podocytes, mature kidney cells responsible for filtering blood inside the nephron, can revert to a state resembling NPCs, meaning fully developed cells can return to a more youthful, progenitor-like phase. Lead author Zhongwei Li stated that the breakthrough could accelerate drug discovery, deepen understanding of the genetic roots of kidney development and disease, and provide a reliable supply of nephron progenitor cells as essential building blocks for synthetic kidneys used in future renal-replacement therapies.

In a separate development, Auxilium Biotechnologies has achieved a historic breakthrough in regenerative medicine by successfully 3D-printing living kidney and liver tissues aboard the International Space Station under microgravity conditions for the first time. The automated AMP-1 platform, using cellular structures and tissue designs developed by specialists at the Wake Forest Institute for Regenerative Medicine, achieved high-precision, multi-purpose biomanufacturing. Key achievements of the space mission included the first-ever production of living human kidney tissue in space, the first fully bioprinted functional liver tissue in orbit, the first simultaneous production of three different tissue types during a single mission, and the manufacturing of a batch of 28 functional nerve repair implants. Thanks to the microgravity environment, scientists achieved an exceptionally uniform distribution of cells throughout the tissue structures, opening up possibilities for creating complex biological products and eventually manufacturing fully functional artificial organs. The capsule carrying the samples splashed down off the coast of California at 5:11 a.m. Pacific Time on June 17. The main commercial and scientific goal of the project is to create organoids, three-dimensional miniature models of human organs, which pharmaceutical giants and research laboratories use to study disease mechanisms, test drug safety, and model treatment responses. The ability to print organoids directly in space would give researchers autonomous access to experiments and eliminate dependence on spacecraft launch schedules. Auxilium is developing a long-term strategy to integrate its printers into future commercial orbital stations, including projects such as Vast and Starlab, and the technology is expected to be scaled up to support long-duration interplanetary missions and provide autonomous medical care at permanent lunar bases.